Show pageOld revisionsBacklinksFold/unfold allBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ======= MEF2A ======= == Gene Information == * **<color #00a2e8>Official Symbol</color>**: MEF2A * **<color #00a2e8>Official Name</color>**: myocyte enhancer factor 2A * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=4205|4205]] * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q02078|Q02078]] * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=MEF2A&organism=9606|BioGRID]] * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20MEF2A|Open PubMed]] * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/600660|Open OMIM]] == Function Summary == * **<color #00a2e8>Entrez Summary</color>**: The protein encoded by this gene is a DNA-binding transcription factor that activates many muscle-specific, growth factor-induced, and stress-induced genes. The encoded protein can act as a homodimer or as a heterodimer and is involved in several cellular processes, including muscle development, neuronal differentiation, cell growth control, and apoptosis. Defects in this gene could be a cause of autosomal dominant coronary artery disease 1 with myocardial infarction (ADCAD1). Several transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2010]. * **<color #00a2e8>UniProt Summary</color>**: N/A <button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button> <button type='primary' size='sm' modal='GO_terms'>GO Terms</button> <modal id='Pfam_Domains' size='lg' title='Pfam Domains'> |SRF-TF| |HJURP C| </modal> <modal id='GO_terms' size='lg' title='GO Terms'> |ERK5 cascade| |ventricular cardiac myofibril assembly| |ventricular cardiac muscle cell development| |ventricular cardiac muscle cell differentiation| |mitochondrion distribution| |mitochondrial genome maintenance| |cardiac myofibril assembly| |histone acetyltransferase binding| |positive regulation of cardiac muscle hypertrophy| |positive regulation of muscle hypertrophy| |activating transcription factor binding| |positive regulation of glucose import| |positive regulation of glucose transmembrane transport| |mitochondrion localization| |SMAD binding| |regulation of glucose import| |regulation of cardiac muscle hypertrophy| |dendrite morphogenesis| |regulation of muscle hypertrophy| |cardiac muscle cell development| |RNA polymerase II transcription factor binding| |cardiac cell development| |myofibril assembly| |regulation of glucose transmembrane transport| |cellular response to calcium ion| |regulation of muscle adaptation| |positive regulation of muscle cell differentiation| |cardiac muscle cell differentiation| |cardiac conduction| |dendrite development| |cellular component assembly involved in morphogenesis| |histone deacetylase binding| |actomyosin structure organization| |cardiocyte differentiation| |multicellular organismal signaling| |striated muscle cell development| |muscle cell development| |response to calcium ion| |regulation of muscle cell differentiation| |cardiac muscle tissue development| |cellular response to metal ion| |striated muscle cell differentiation| |positive regulation of transmembrane transport| |transcription factor complex| |cellular response to inorganic substance| |regulation of muscle system process| |nuclear chromatin| |regulation of heart contraction| |muscle cell differentiation| |striated muscle tissue development| |transcription coactivator activity| |regulation of blood circulation| |muscle organ development| |muscle tissue development| |RNA polymerase II regulatory region sequence-specific DNA binding| |response to metal ion| |MAPK cascade| |signal transduction by protein phosphorylation| |chromatin binding| |sequence-specific DNA binding| |cell morphogenesis involved in neuron differentiation| |mitochondrion organization| |DNA-binding transcription activator activity, RNA polymerase II-specific| |supramolecular fiber organization| |protein kinase binding| |muscle structure development| |neuron projection morphogenesis| |plasma membrane bounded cell projection morphogenesis| |protein heterodimerization activity| |cell projection morphogenesis| |actin cytoskeleton organization| |RNA polymerase II proximal promoter sequence-specific DNA binding| |cell part morphogenesis| |heart development| |response to inorganic substance| |cell morphogenesis involved in differentiation| |regulation of transmembrane transport| |actin filament-based process| |organelle localization| |regulation of system process| |transcription, DNA-templated| |nucleic acid-templated transcription| |RNA biosynthetic process| |neuron projection development| |DNA-binding transcription factor activity| |cell morphogenesis| |organelle assembly| |neuron development| |cellular component morphogenesis| |negative regulation of transcription by RNA polymerase II| |circulatory system development| |anatomical structure formation involved in morphogenesis| |apoptotic process| |positive regulation of cell differentiation| |protein phosphorylation| |positive regulation of transport| |neuron differentiation| |programmed cell death| |cell death| |nucleobase-containing compound biosynthetic process| |cytoskeleton organization| |plasma membrane bounded cell projection organization| |cell projection organization| |heterocycle biosynthetic process| |aromatic compound biosynthetic process| |negative regulation of transcription, DNA-templated| |positive regulation of transcription by RNA polymerase II| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |phosphorylation| |organic cyclic compound biosynthetic process| |negative regulation of RNA metabolic process| |positive regulation of developmental process| |negative regulation of cellular macromolecule biosynthetic process| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |negative regulation of cellular biosynthetic process| |generation of neurons| |positive regulation of transcription, DNA-templated| |negative regulation of biosynthetic process| |DNA-binding transcription factor activity, RNA polymerase II-specific| |neurogenesis| |cellular nitrogen compound biosynthetic process| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |cell development| |RNA metabolic process| |intracellular signal transduction| |cellular macromolecule biosynthetic process| |negative regulation of gene expression| |positive regulation of RNA metabolic process| |positive regulation of multicellular organismal process| |tissue development| |macromolecule biosynthetic process| |regulation of cell differentiation| |regulation of transport| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |gene expression| |positive regulation of biosynthetic process| </modal> \\ === CRISPR Data === <button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button> <button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button> <button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button> <modal id='Compound_Hit' size='lg' title='Compound Hit'> ^Screen^Score^ |[[:results:exp30|Rapamycin 10μM R00 exp30]]|-2.74| |[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.43| |[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|-2.3| |[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|-2.28| |[[:results:exp15|Cycloheximide 0.2μM R00 exp15]]|-2.08| |[[:results:exp31|Rifampicin 1μM R00 exp31]]|-2.05| |[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-2.04| |[[:results:exp106|UM131593 0.2μM R03 exp106]]|-1.95| |[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-1.94| |[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-1.94| |[[:results:exp316|Geldanamycin 0.015 to 0.025μM on day4 R07 exp316]]|-1.8| |[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-1.8| |[[:results:exp169|BH1 1μM R04 exp169]]|-1.77| |[[:results:exp14|Cycloheximide 0.02μM R00 exp14]]|-1.77| |[[:results:exp530|Thioridazine 5μM R08 exp530]]|-1.77| |[[:results:exp269|Bisphenol A 100μM R06 exp269]]|-1.71| |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-1.71| |[[:results:exp272|CHIR-124 0.04μM R06 exp272]]|1.75| |[[:results:exp50|Nicotinamide 2000μM R01 exp50]]|1.76| |[[:results:exp46|HMS-I1 1μM R01 exp46]]|1.8| |[[:results:exp51|Nifuroxazide 1μM R01 exp51]]|2.35| </modal> <modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'> No correlation found to any other genes in chemogenomics. </modal> <modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'> Global Fraction of Cell Lines Where Essential: 0/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| </modal> == Essentiality in NALM6 == * **<color #00a2e8>Essentiality Rank</color>**: 3899 * **<color #00a2e8>Expression level (log2 read counts)</color>**: 7.57 <button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button> <modal id='Dist_expr' size='lg' title='MEF2A Expression in NALM6 Cells: 7.57'> {{:chemogenomics:nalm6 dist.png?nolink |}} </modal> Last modified: 2026/01/07 22:36by 127.0.0.1